Swissmedic Approves Temporary Distribution of NaCl 0.9% Infusion in Foreign Packaging

On November 26, 2025, Swissmedic announced the temporary approval for distribution of NaCl 0.9% infusion solution…

Critical Updates: Field Safety Notices Issued for Medical Devices (Nov 17–21, 2025)

New updates on medical device safety concern all clinical, quality, and regulatory professionals. Between November 17…

Important Safety Notice: Updated Safety Information Missing from Moclobemide 150mg Tablets Packaging

On November 25, 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) issued a Class 4…

Swissmedic Announces Financial Consolidation Plan Amid Regulatory Priorities

Swissmedic, Switzerland’s key regulatory authority for therapeutic products, has outlined measures to strengthen its financial position.…

Critical Updates: Field Safety Notices Issued from 10–14 November 2025

Between 10 and 14 November 2025, significant Field Safety Notices (FSNs) were announced, carrying potential implications…

Swissmedic Confirms First Authorisation for Lutathera®: Key Regulatory Update

On November 22, 2025, Swissmedic published an important regulatory update announcing the first authorisation of Lutathera®,…

Swissmedic Expands Use of Breyanzi®: Updated Authorization Details

On November 22, 2025, Swissmedic announced the extension of the therapeutic indication for Breyanzi® (lisocabtagene maraleucel).…

Swissmedic Authorizes 18F-PSMA-1007 ZRP®: Key Insights for Regulatory and Clinical Teams

On November 22, 2025, Swissmedic officially granted the first authorization of 18F-PSMA-1007 ZRP®. This approval represents…

Swissmedic Grants First Authorisation of Radelumin®: A Regulatory Milestone

Swissmedic has announced the first authorisation of Radelumin®, marking a significant regulatory achievement. Effective November 22,…

Swissmedic Update: Expanded Indication Approval for NexoBrid®

Swissmedic, Switzerland’s medical regulatory authority, has announced an important update regarding NexoBrid®. On November 22, 2025,…